Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

Lisa Rydén; Karin Jirström; Pär-Ola Bendahl; Mårten Fernö; Bo Nordenskjöld; Olle Stål; Sten Thorstenson; Per-Ebbe Jönsson; Göran Landberg

doi:10.1200/JCO.2005.08.126

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

Lisa Rydén, Karin Jirström, Pär-Ola Bendahl, Mårten Fernö, Bo Nordenskjöld, Olle Stål, Sten Thorstenson, Per-Ebbe Jönsson, Göran Landberg

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	4695-4704
Journal	Journal of Clinical Oncology
Volume	23
Issue number	21
DOIs	https://doi.org/10.1200/JCO.2005.08.126
Publication status	Published - 2005

Subject classification (UKÄ)

Cancer and Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1200/JCO.2005.08.126

http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=16034044&dopt=Abstract

Cite this

Rydén, L., Jirström, K., Bendahl, P.-O., Fernö, M., Nordenskjöld, B., Stål, O., Thorstenson, S., Jönsson, P.-E., & Landberg, G. (2005). Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Journal of Clinical Oncology, 23(21), 4695-4704. https://doi.org/10.1200/JCO.2005.08.126

Rydén, Lisa ; Jirström, Karin ; Bendahl, Pär-Ola et al. / Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. In: Journal of Clinical Oncology. 2005 ; Vol. 23, No. 21. pp. 4695-4704.

@article{0e0cedc299ef415195d34bf8bcc66f06,

title = "Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.",

author = "Lisa Ryd{\'e}n and Karin Jirstr{\"o}m and P{\"a}r-Ola Bendahl and M{\aa}rten Fern{\"o} and Bo Nordenskj{\"o}ld and Olle St{\aa}l and Sten Thorstenson and Per-Ebbe J{\"o}nsson and G{\"o}ran Landberg",

year = "2005",

doi = "10.1200/JCO.2005.08.126",

language = "English",

volume = "23",

pages = "4695--4704",

journal = "Journal of Clinical Oncology",

issn = "1527-7755",

publisher = "Lippincott Williams & Wilkins",

number = "21",

}

Rydén, L , Jirström, K , Bendahl, P-O , Fernö, M, Nordenskjöld, B, Stål, O, Thorstenson, S, Jönsson, P-E & Landberg, G 2005, 'Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.', Journal of Clinical Oncology, vol. 23, no. 21, pp. 4695-4704. https://doi.org/10.1200/JCO.2005.08.126

Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. / Rydén, Lisa ; Jirström, Karin ; Bendahl, Pär-Ola et al.
In: Journal of Clinical Oncology, Vol. 23, No. 21, 2005, p. 4695-4704.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer.

AU - Rydén, Lisa

AU - Jirström, Karin

AU - Bendahl, Pär-Ola

AU - Fernö, Mårten

AU - Nordenskjöld, Bo

AU - Stål, Olle

AU - Thorstenson, Sten

AU - Jönsson, Per-Ebbe

AU - Landberg, Göran

PY - 2005

Y1 - 2005

U2 - 10.1200/JCO.2005.08.126

DO - 10.1200/JCO.2005.08.126

M3 - Article

SN - 1527-7755

VL - 23

SP - 4695

EP - 4704

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 21

ER -

Rydén L , Jirström K , Bendahl PO , Fernö M, Nordenskjöld B, Stål O et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. Journal of Clinical Oncology. 2005;23(21):4695-4704. doi: 10.1200/JCO.2005.08.126